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We report the successful treatment of a patient withhomocystinuria with combination chemotherapy and
radiotherapy for a non-small cell lung cancer.
A 62-year-old man presented in April 2004 to the Acute
Medical Unit with three episodes of hemoptysis. He denied
shortness of breath or infective symptoms. At age 24 years,
he had been diagnosed as having homocystinuria after bilat-
eral downward lens dislocations and had been successfully
treated with niacin, betaine, and pyridoxine supplements.
On initial assessment, he had a Marfanoid appearance,
and his respiratory and cardiovascular systems were unre-
markable. Blood tests demonstrated normal hematology and
biochemistry, but D dimer was elevated at 928. An electro-
cardiograph showed Right Bundle Branch Block, and chest
radiograph was unremarkable. A computed tomography-pul-
monary angiography showed a filling defect in left upper lobe
pulmonary artery, which, although consistent with pulmonary
embolus, was not typical. Anticoagulation and a repeat com-
puted tomographic scan was advised 4 weeks later to exclude
a neoplastic lesion.
This repeat scan demonstrated that the left upper lobe
bronchus was occluded by a soft tissue mass (Figure 1). In
addition, there was a 12-mm subcarinal lymph node, a
heterogeneous 6.5-cm left adrenal mass containing a small
area of fat and calcification, and the liver contained hem-
angiomas. The patient underwent bronchoscopy, which
confirmed a squamous cell carcinoma occluding the left
upper lobe bronchus.
The patient was thus referred to the Edinburgh Cancer
Centre, and treatment options were discussed at the Lung
Cancer Multi-disciplinary Meeting. The appearances of the
adrenal mass were inconclusive, consistent with a benign
adenoma, a metastatic deposit, or a primary adrenal tumor.
Urinary screening for catecholamines was negative for pha-
echromocytoma; therefore, the patient underwent a biopsy of
his adrenal gland, which showed vascularized stroma but no
evidence of metastatic cancer, although there was the possi-
bility of it representing scarring within an adrenal neoplasm.
In light of this biopsy result, we assessed the response of both
the lung and adrenal lesions to chemotherapy. A response in
the adrenal tumor would have been consistent with a meta-
static tumor.
The patient received a total of four cycles of carboplatin
at area under the curve 6 on day 1 and gemcitabine 1200
mg/m2 on days 1 and 8 of a 21-day cycle. His second cycle
was delayed by a week because of neutropenia, and the day
8 gemcitabine on cycle 3 was omitted for the same reason. He
tolerated the treatment well, with only grade 2 fatigue as a
significant side effect.
Computed tomographic scans performed after the sec-
ond and fourth cycles demonstrated a minor response from
the lung primary, although measurements remained un-
changed and the adrenal mass was reduced slightly, from 65
mm to 53 mm. To clarify the true tumor stage, the patient
underwent a fludeoxyglucose-positron emission tomography
scan, which demonstrated only increased uptake at the site of
the primary, with no mediastinal or metastatic deposits.
Accordingly, he proceeded to radical radiotherapy, receiving
55 Gy in 20 fractions over 4 weeks, which he tolerated well,
and at follow up in December 2005, he was doing well with
no evidence of recurrent disease.
DISCUSSION
Homocystinuria is an autosomal recessive condition,
which, in the classic form, is the result of a mutation of the
long arm of chromosome 21 (21q22.3). This results in a
reduction of cystathionine synthase and, hence, accumulation
of homocystine. It is characterized by Marfanoid appear-
ances: pale skin and brittle hair, ocular changes (including
downward lens dislocation), developmental delay, psychiatric
illnesses, osteoporosis, and vascular events, which include
both embolic and thrombotic episodes.1 A quarter of patients
die of a vascular event before their 30th birthday.1 Treatment
includes the use of pyridoxine, betaine, and high-dose folic
acid.2
This patient had an abnormal presentation; he had
initially been diagnosed with Marfan’s syndrome until, at age
24 years, he developed bilateral downward lens dislocation,
which is pathonmonic of homocystinuria. He was then told
that he was the oldest known presentation of homocystinuria.
The patient has a previous psychiatric diagnosis, well
controlled on medication, and hypertension, but had no other
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signs of vascular disease or osteoporosis. His homocystine levels
had not previously responded to methionine deplete diet or to
vitamin B injections and high-dose folic acid, but his disease had
been controlled with niacin 250 mg four times a day, betaine 10
mg twice a day, and pyridoxine 800 mg once a day.
Before we began chemotherapy with this patient, we
conducted a MEDLINE search to investigate any previous
reports of potential problems in administering cytotoxic
agents to a patient with this condition. No previous reports of
a patient with homocystinuria receiving chemotherapy could
be identified.
Theoretically, the chemotherapy could affect the pa-
tient’s metabolism, or there could be altered metabolism of
anticancer agents.3 Studies have indicated that children with
acute lymphoblastic leukemia have elevated homocysteine
levels before chemotherapy (likely related to intracellular
folate deficiency and export of homocysteine from leukemic
cells) and that these levels transiently increase post metho-
trexate (an antifolate drug) before decreasing after three
methotrexate adminstrations to levels seen in controls.4 Our
patient had normal B12 and folate levels. In patients with
homocystinuria, it is possible that the administration of anti-
folate chemotherapy such as methotrexate or pemetrexed could
have significant adverse effects as the reduced availability of
folates could lead to decreased availability of the enzyme that
converts homocysteine back to methionine (Figure 2).
A study has also shown that the administration of a
6-azauridine triacetate, a pyramidine nucleoside analogue
previously used in mycosis fungoides, psoriasis, and tropho-
blastic malignancies, caused amino acid changes similar to
homocystinuria.5 The use of gemcitabine (also a nucleoside
analogue that inhibits DNA synthesis) and carboplatin could
potentially have upset the patient’s metabolic balance, or the
drugs could have been metabolized less efficiently, leading to
increased side effects; however, glutathione (involved in
inactivation of platinum drugs) levels have been found to be
normal in patients with homocystinuria.6 However, in our
patient, chemotherapy was safely administered with no sig-
nificant clinical complications.
SUMMARY
In this case, we present a patient with a late presenta-
tion of homocystinuria who experienced few of the compli-
cations and lived longer than the usual life span of patients
with this condition. He is possibly the first patient with
homocystinuria to receive chemotherapy, and there were no
obvious toxicities from different metabolism of the chemo-
therapy agents (carboplatin and gemcitabine). However, there
is a significant theoretical risk of the use of antifolates in
patients with homocystinuria. As the life expectancy of pa-
tients with homocystinuria increases with more aggressive
management of vascular risk factors, it is likely that such
patients may develop neoplasms needing chemotherapy.
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FIGURE 1. Left upper lobe lesion with associated collapse.
FIGURE 2. Formation and fate of homocysteine. Homocys-
teine conversion back to methionine is catalyzed by homo-
cysteine-tetrahydrofolate methyltransferase (enzyme 1). Ho-
mocystinuria is an inherited deficiency of cystathionine
synthase. THF, tetrahydrofolate.
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